Saturday, October 31, 2026

USD/EUR Bullish Momentum: 0.826% Up In The Last 24 Hours

USD/EUR Bullish Momentum: 0.826% Up In The Last 24 Hours

(VIANEWS) - USD/EUR (USDEUR) has been up by 0.8263% for the last session's close. At 15:10 EST on Friday, 12 April, USD/EUR (USDEUR) is $0.94.

USD/EUR (USDEUR) Range

Concerning USD/EUR's daily highs and lows, it's 0.837% up from its trailing 24 hours low of $0.93 and 0.815% up from its trailing 24 hours high of $0.93.

USD/EUR's yearly highs and lows, it's 5.942% up from its 52-week low and 1.818% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was 0.16%, 0.07%, and 0.25%, respectively.

USD/EUR's highest amplitude of average volatility was 0.26% (last week), 0.27% (last month), and 0.25% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be oversold (<=20).

News about

  • Usd/jpy refreshes 34-year highs above 153.00 following US PPI data. According to FXStreet on Thursday, 11 April, "The USD/JPY climbed during the North American session and remains above the 153.00 figure despite Japanese authorities jawboning on excessive Japanese Yen (JPY) movements. ", "Given the fact the USD/JPY has broken the 153.00 barrier, the next resistance level would be the June 1990 monthly high at 155.78, followed by the April 1990 pivot high at 160.32. "
  • According to FXStreet on Thursday, 11 April, "At the time of writing, USD/JPY is trading 0.22% lower on the day to trade at 152.85"
  • According to FXStreet on Wednesday, 10 April, "The stronger dollar and rising US yields motivated USD/JPY to surge to the boundaries of the 153.00 hurdle. "
  • Usd/jpy hits nearly 34-year peak amid surging US inflation and treasury yields. According to FXStreet on Wednesday, 10 April, "The USD/JPY rallied to an almost 34-year high after a hotter-than-expected inflation report in the United States (US) sent US Treasury yields soaring. ", "From a technical standpoint, the USD/JPY is trading at levels that were seen in the 1990s. "
  • Usd/jpy hovers around 153.00, the highest level since July 1990, eyes on intervention risks. According to FXStreet on Wednesday, 10 April, "The USD/JPY pair trades on a weaker note near 153.00 after retreating from the highest level since July 1990, nearly 153.24, on Thursday during the early Asian session. ", "The officials emphasized the need to keep interest rates higher for longer, which boosts the Greenback and acts as a tailwind for the USD/JPY pair. "

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com